


**BE IT KNOWN** that I, Sunita Kumeri of, 268 Bath Road, Slough, Berkshire United Kingdom a duly authorised Notary Public

**CERTIFY ONLY** that Brian Michael Howes who is well known to me and who is duly authorised by GlaxoSmithKline ("the Company") to represent them in this matter has today caused the annexed Certificate of GMP Compliance of a Manufacturer issued to UCB Pharma SA to be produced to me and has represented to me on behalf of the company that the said document is a true copy of the original electronic document produced to him.

**SIGNED** and sealed at 268 Bath Road, Slough, Berkshire aforesaid on 24<sup>th</sup> June 2020.



Sunita Kumeri  
Notary Public  
England and Wales

Protocol No. 35/20



**APOSTILLE**

(Convention de La Haye du 5 octobre 1961)

1. **Country:** United Kingdom of Great Britain and Northern Ireland  
Pays / País:

**This public document**

Le présent acte public / El presente documento público

2. **Has been signed by**  
a été signé par Sunita Kumeri  
ha sido firmado por

3. **Acting in the capacity of**  
agissant en qualité de Notary Public  
quien actúa en calidad de

4. **Bears the seal / stamp of**  
est revêtu du sceau / timbre de The Said Notary Public  
y está revestido del sello / timbre de

**Certified**

Attesté / Certificado

5. **at** London  
à / en

6. **the** 25 June 2020  
le / el día

7. **by** Her Majesty's Principal Secretary of State  
par / por for Foreign and Commonwealth Affairs

8. **Number** APO-1937147  
sous no / bajo el numero

9. **Seal / stamp**  
Sceau / timbre  
Sello / timbre



10. **Signature** R. James  
Signature  
Firma

This Apostille is not to be used in the UK and only confirms the authenticity of the signature, seal or stamp on the attached UK public document. It does not confirm the authenticity of the underlying document. Apostilles attached to documents that have been photocopied and certified in the UK confirm the signature of the UK official who conducted the certification only. It does not authenticate either the signature on the original document or the contents of the original document in any way.

If this document is to be used in a country not party to the Hague Convention of the 5th of October 1961, it should be presented to the consular section of the mission representing that country

To verify this apostille go to [www.verifyapostille.service.gov.uk](http://www.verifyapostille.service.gov.uk)

**Federal Agency for Medicines and Health Products**

CERTIFICATE NUMBER: **BE/GMP/2016/100**

**CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER**

**Part 1**

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Belgium confirms the following:

The manufacturer: **UCB Pharma SA**

Site address: **Chemin du Foriest, Braine-l'Alleud, 1420, Belgium**

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. **194 H** in accordance with Art. 40 of Directive 2001/83/EC transposed in the following national legislation:

**Article 12 bis, § 1 of the Law of 25th March 1964 related to the Medicinal Products**

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2016-09-09**, it is considered that it complies with :

- The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC<sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

<sup>1</sup> The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

<sup>2</sup> Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>3</sup> These requirements fulfil the GMP recommendations of WHO.

## Part 2

Human Medicinal Products	
<b>1 MANUFACTURING OPERATIONS</b>	
<b>1.2</b>	<b>Non-sterile products</b>
	<i>1.2.1 Non-sterile products (processing operations for the following dosage forms)</i> 1.2.1.1 Capsules, hard shell 1.2.1.13 Tablets
	<i>1.2.2 Batch certification</i>

Any restrictions related to the scope of this certificate :

Building	Room	Line/equipment	QC testing	Products
<b>B3</b>	<i>formes sèches</i>			

Clarifying remarks (for public users)

*The duration of validity of this GMP-certificate has been extended with 2 years.*

2020-05-12

Name and signature of the authorised person of the  
Competent Authority of Belgium

-----  
**Confidential**  
**Federal Agency for Medicines and Health Products**  
Tel: **Confidential**  
Fax: **Confidential**